In 2025, sales are anticipated to grow by a high single-digit percentage at CER. Sanofi (SNY) confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Faces EU Setback for Rezurock Amidst Positive Developments
- ImageneBio initiated with an Outperform at Leerink
- Sanofi: Buy Rating Affirmed on Strong Financials and Promising Growth Prospects
- Ventyx ‘unequivocally impressive data’ should spur Sanofi, says Clear Street
- Sanofi, Medidata expand partnership